mCRPC
Medical abbreviation · Hematology and Oncology
| Stands for | Metastatic castration-resistant prostate cancer |
|---|---|
| Categories | Medical |
mCRPC stands for Metastatic castration-resistant prostate cancer, a hematology and oncology abbreviation.
Advanced prostate cancer that has spread and keeps growing despite testosterone being suppressed to castrate levels (below 50 ng/dL) by hormone therapy. Rising PSA, new bone lesions and pain are typical signs.
Example: mCRPC progressing on enzalutamide; PSMA PET avid, starting lutetium-177 PSMA-617.
Usage notes
Treatment options include androgen receptor pathway inhibitors (abiraterone, enzalutamide), taxane chemotherapy (docetaxel, cabazitaxel), radium-223 for bone metastases, the radioligand lutetium-177 PSMA-617 (approved in 2022) and PARP inhibitors such as olaparib for tumors with DNA repair gene mutations. Hormone therapy is continued even after resistance develops. The lowercase m stands for metastatic.
Related abbreviations
More hematology and oncology abbreviations
- JAK2 – Janus kinase 2
- KPS – Karnofsky Performance Status
- KRAS – Kirsten rat sarcoma viral oncogene homolog
- LA – Lupus anticoagulant
- MAHA – Microangiopathic hemolytic anemia
- MCL – Mantle cell lymphoma
- MDS – Myelodysplastic syndrome
- mets – Metastases
- MGUS – Monoclonal gammopathy of undetermined significance
- MM – Multiple myeloma
- MPN – Myeloproliferative neoplasm
- MRD – Minimal residual disease
See all 144 hematology and oncology abbreviations →
This entry is for general education and is not medical advice. Abbreviation use varies between institutions; always confirm in context.